Jones JL - Search Results

1

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Jones JL, et al. Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21. Brain. 2010. PMID: 20659956 Clinical Trial.

2

Spotlight on alemtuzumab.

Jones JL, Coles AJ. Jones JL, et al. Int MS J. 2009 Sep;16(3):77-81. Int MS J. 2009. PMID: 19878629 Review.

3

First use of alemtuzumab in Balo's concentric sclerosis: a case report.

Brown JW, Coles AJ, Jones JL. Brown JW, et al. Among authors: jones jl. Mult Scler. 2013 Oct;19(12):1673-5. doi: 10.1177/1352458513498129. Epub 2013 Jul 25. Mult Scler. 2013. PMID: 23886830

4

Campath-1H treatment of multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Neurodegener Dis. 2008;5(1):27-31. doi: 10.1159/000109935. Neurodegener Dis. 2008. PMID: 18075272 Review.

5

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A, Coles AJ. Jones JL, et al. J Clin Invest. 2009 Jul;119(7):2052-61. doi: 10.1172/JCI37878. Epub 2009 Jun 22. J Clin Invest. 2009. PMID: 19546505 Free PMC article.

6

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. Thompson SA, et al. Among authors: jones jl. J Clin Immunol. 2010 Jan;30(1):99-105. doi: 10.1007/s10875-009-9327-3. Epub 2009 Sep 10. J Clin Immunol. 2010. PMID: 19763798

7

New treatment strategies in multiple sclerosis.

Jones JL, Coles AJ. Jones JL, et al. Exp Neurol. 2010 Sep;225(1):34-9. doi: 10.1016/j.expneurol.2010.06.003. Epub 2010 Jun 12. Exp Neurol. 2010. PMID: 20547155 Review.

8

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Hill-Cawthorne GA, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5. J Neurol Neurosurg Psychiatry. 2012. PMID: 22056965

9

Immune competence after alemtuzumab treatment of multiple sclerosis.

McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. McCarthy CL, et al. Among authors: jones jl. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7. Neurology. 2013. PMID: 23925762 Free PMC article.

10

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL. Azzopardi L, et al. Among authors: jones jl. J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):795-8. doi: 10.1136/jnnp-2013-307042. Epub 2013 Dec 24. J Neurol Neurosurg Psychiatry. 2014. PMID: 24368840

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

804 results

Search Page

Filters